Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
$119.99
$119.23
$99.74
$120.05
$4.72B0.47148,695 shs390,921 shs
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
$1.84
-3.2%
$1.90
$1.12
$4.20
$136.79M0.92279,311 shs93,530 shs
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
$1.96
+51.9%
$1.15
$7.80
$12.38
$33.81MN/A41,322 shs7.83 million shs
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
$4.13
+5.9%
$2.18
$1.11
$6.40
$555.47M2.331.79 million shs6.27 million shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
0.00%0.00%0.00%0.00%0.00%
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
+2.15%-5.00%+9.20%+0.26%+27.52%
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
0.00%-3.70%+8.33%+5.69%-62.86%
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
-3.47%-16.84%+141.49%+214.52%-38.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
N/AN/AN/AN/AN/AN/AN/AN/A
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
1.2234 of 5 stars
3.31.00.00.00.00.00.6
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
3.8264 of 5 stars
4.41.00.00.03.05.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
0.00
N/AN/AN/A
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
2.50
Moderate Buy$6.50253.26% Upside
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
0.00
N/AN/AN/A
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
2.75
Moderate Buy$9.25123.97% Upside

Current Analyst Ratings Breakdown

Latest CBPO, PRME, JATT, and IKT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/16/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$8.00
5/27/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$10.00 ➝ $1.50
5/20/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $6.00
5/20/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
5/20/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Neutral
5/19/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $12.00
(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
$503.70M9.38$5.01 per share23.93$45.09 per share2.66
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
N/AN/AN/AN/A$1.78 per shareN/A
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/AN/A$0.07 per share27.08($0.53) per shareN/A
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
$3.85M144.43N/AN/A$1.37 per share3.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
$138.81M$4.2833.5227.90N/A27.43%8.32%7.64%N/A
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/A
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
$6.85MN/A0.00N/AN/A-49.58%2.84%N/A
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
-$198.13M-$1.61N/AN/AN/AN/A-107.87%-74.97%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
N/AN/AN/AN/AN/A
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
N/AN/AN/AN/AN/A
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/AN/AN/AN/AN/A
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
$1.4535.01%N/AN/A N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
N/A
12.01
10.13
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
N/A
0.85
0.85
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/A
0.15
0.15
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
N/A
6.50
6.50

Institutional Ownership

CompanyInstitutional Ownership
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
34.77%
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
3.81%
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
47.97%
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
70.37%

Insider Ownership

CompanyInsider Ownership
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
2.73%
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
7.30%
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
20.00%
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
22.93%
CompanyEmployeesShares OutstandingFree FloatOptionable
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
2,26939.36 millionN/AOptionable
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
674.34 million66.18 millionNot Optionable
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
317.25 million13.80 millionNot Optionable
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
234134.50 million100.38 millionOptionable

Recent News About These Companies

Prime Medicine (NYSE:PRME) Receives Outperform Rating from Wedbush

New MarketBeat Followers Over Time

Media Sentiment Over Time

China Biologic Products stock logo

China Biologic Products NASDAQ:CBPO

China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, auto-immune deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.

Inhibikase Therapeutics stock logo

Inhibikase Therapeutics NYSE:IKT

$1.84 -0.06 (-3.16%)
Closing price 04:00 PM Eastern
Extended Trading
$1.85 +0.01 (+0.54%)
As of 04:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

JATT Acquisition stock logo

JATT Acquisition NYSE:JATT

$1.96 +0.67 (+51.94%)
As of 07/17/2025

JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.

Prime Medicine stock logo

Prime Medicine NYSE:PRME

$4.13 +0.23 (+5.90%)
Closing price 04:00 PM Eastern
Extended Trading
$4.08 -0.04 (-1.09%)
As of 04:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.